glp1Tariff appliesAnnex III — Jul 31 2026

Wegovy Tariff Rate & July 31, 2026 Deadline

Wegovy (Semaglutide) — manufactured by Novo Nordisk in Denmark. Treats chronic weight management. Typical US retail $1,349 per month.

Tariff breakdown

Applicable rate: 100% (Annex III)
Effective date: 2026-07-31 (98 days away)
Manufacturer: Novo Nordisk
Country of origin: Denmark
Annex III?: Yes
Current monthly retail: $1,349

Projected monthly retail, by pass-through scenario

Scenario	Pass-through	New monthly retail	Annual increase
Conservative	30%	$1,754	+$4,856
Likely	50%	$2,024	+$8,094
Worst case	100%	$2,698	+$16,188

Scenarios based on historical brand-pharma cost-shock pass-through. Not a forecast.

HTS classification

HTS 3004.90.9299

Semaglutide (higher-dose) for chronic weight management, HTS 3004.90. Novo Nordisk manufactures in Denmark.

Source: USITC Harmonized Tariff Schedule, 2026 Revision 2 — hts.usitc.gov

Alternatives: generics, biosimilars & US-made options

Zepbound (tirzepatide, Eli Lilly)

us made

FDA-approved for chronic weight management; US-manufactured, tariff-exempt. Likely the primary substitute.

Compounded semaglutide

therapeutic alternative

FDA-discontinued shortage exception removed in 2025; availability is narrow and quality variable. Not recommended without clinical guidance.

Always consult your prescriber before switching medications. Biosimilars and generics are not interchangeable in every state without physician approval.

FAQ: Wegovy and the 2026 tariff

Will my Wegovy prescription cost more after July 31, 2026?

Likely yes. Wegovy is manufactured in Denmark and is not exempt. Our conservative-case scenario assumes 30% pass-through (retail +$405/month), our likely-case 50% (+$675/month), and worst-case full pass-through (+$1,349/month).

Can I switch to a generic version of Semaglutide?

No FDA-approved generic of Semaglutide is widely available in the US as of 2026 Q2. Biosimilars or therapeutic alternatives (listed above) are the practical substitutes.

Is Wegovy on the Medicare negotiated-price list?

Wegovy is not among the first-round Medicare-negotiated drugs effective 2026. Check CMS announcements for subsequent negotiation rounds.

Importing pharmaceuticals commercially?

This page covers consumer drug pricing. For business imports (including finished-dose pharmaceuticals), use the full US import tariff calculator with HTS classification and Section 301/232/122 breakdown.

Disclaimer: Informational estimates based on public list prices, the April 2, 2026 Proclamation text, and USITC HTS data. Not medical, legal, or financial advice.

Talk to your doctor, pharmacist, and insurer about your specific medication.